Breast cancer is still the most common malignancy among women with half a million deaths every year and one in nine of all females in the western world developing it sometime in their lives. Oestrogen is the major female sex hormone, crucial for the normal sex development and functioning of female organs and tissues, but also with a crucial role in the survival and development of many breast tumours. The hormone acts by binding to specific ER (ER-alpha and ER-beta) in a lock-and-key-mechanism that results in the activation, on the target tissue, of genes involved in cell survival and proliferation.
The role of oestrogen in cancer was first noticed about 100 years ago when researchers observed that removal of the ovaries – the major place for oestrogen production - in women with breast cancer substantially increased their chance of survival. We know now that this effect results from the fact that about 75% of human breast cancers are ER positive (mostly ER-alpha) and, as result, their grow and survival is directly dependent on oestrogen. This is also why men, that do not have ovaries and have much less oestrogen, present much lower breast cancer rates in comparison to women.
But to have ER-positive breast cancer is not only bad news since this type of tumours has the best prognosis, most probably because the hormonal therapies used in these cases (which disrupt oestrogen-ER activation) can be very effective.
Nevertheless, after an initial period of response many ER-positive tumours develop treatment resistance - even if in most of cases they maintain their oestrogen receptors - leading to disease relapses. This is believed to result from “over-activation” of ER, and consequent by-pass of the hormonal therapy effect, by growth factors, another type of hormones capable of activate ER. These cases, together with the 25% of breast tumours that are ER-negative, present a major challenge to an effective clinical management of the disease. As result it is crucial to understand the molecular and cellular mechanisms behind oestrogen receptors expression and activity for a wider and more effective breast cancer therapy.
In agreement with this idea, Patricia A. Madureira, Eric W.-F Lam and colleagues at Imperial College, London, UK and the University of Hong Kong in China looked for molecules capable of affect ER expression and/or activity, and found that transcription factor FoxM1 (transcription factors are proteins that bind to regulatory regions in the DNA leading to the expression or inhibition of specific genes) is a physiological regulator of ER-alpha expression in breast cancer cells.
Madureira, Lam and colleagues started by analysing cells from 16 different breast tumours to find that in 13 of them FoxM1 and ER-alpha expression showed a high correlation, suggesting some kind of functional link between the two molecules. Other experiments, such as the inhibition or, alternatively the introduction of FoxM1 expression in breast cancers cells, which led, respectively, to the reduction or the increase of ER-alpha levels in these cells, confirmed this role of FoxM1 in ER-alpha regulation.
These are findings that can have important therapeutic value because ER regulation/expression is, as here discussed, directly associated with the oestrogen-mediated mechanism that affects the survival and proliferation of tumour cells, and also, in the cases where hormonal therapy is being used, the control (or not) of the disease. To understand the mechanisms affecting the expression of these molecules is then fundamental to be able to have a better chance interfering and controlling breast cancer, a disease that, according to the World Health Organization, only in 2005 had more than a million of new cases diagnosed.
Piece researched and written by: Catarina Amorim (email@example.com)
Catarina Amorim | alfa
Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg
New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington
Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.
"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...
In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.
A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...
By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.
"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...
COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.
In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...
'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.
Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...
14.10.2016 | Event News
14.10.2016 | Event News
12.10.2016 | Event News
21.10.2016 | Health and Medicine
21.10.2016 | Information Technology
21.10.2016 | Materials Sciences